ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial tests new weapon against advanced uterine cancer
Disease control OngoingThis large, late-stage study is testing whether adding an immunotherapy drug called pembrolizumab to standard chemotherapy works better for treating advanced or recurrent endometrial cancer. It involves over 800 patients with stage III, IV, or returning cancer. The goal is to see…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New hope to stop endometrial cancer from coming back
Disease control OngoingThis study is testing whether adding an immunotherapy drug called pembrolizumab to standard radiation treatment is better at preventing cancer from returning in patients with early-stage endometrial cancer. The trial will compare radiation alone versus radiation plus pembrolizuma…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
Virtual support aims to calm cancer fears
Symptom relief TerminatedThis study aimed to test an online mental health program designed to help women with advanced breast or gynecologic cancers manage their fear of the cancer coming back or getting worse. Participants would have been randomly assigned to either the main program, which taught coping…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Apr 01, 2026 14:43 UTC